Aldosterone lowers protein kinase C (PKC) activity in myocyteenriched cultures from neonatal Sprague-Dawley rat hearts, with activity measured by the transfer of phosphate to myristolated alanine-rich C-kinase substrate, in the presence of Ca 2ϩ , phosphatidylserine, and diolein. The effect is rapid, with a significant effect after 1 min exposure, half maximal at Յ1 nM aldosterone, with steroids showing a hierarchy of potency aldosterone ϭ 9␣ fluorocortisol Ͼ deoxycorticosterone Ͼ corticosterone Ͼ spironolactone. Both Ca 2ϩ -dependent and -independent PKC activity appear equally inhibited by aldosterone, and PMA-stimulated increases in PKC activity appear similarly aldosterone-sensitive. No displaceable binding of [ 3 H]aldosterone to purified PKC can be shown, evidence against a direct effect of aldosterone on PKC; aldosterone does not alter basal or PMA-stimulated PKC activity in cardiac fibroblasts, evidence for a cell-specific mediator of the myocyte effect. Taken with the previous demonstration of the potentiation of aldosterone-specific MR-mediated effects by PKC activation, the present data argue for the existence of a complex cross-talk mechanism between aldosterone and factors affecting PKC activity in the heart. (Endocrinology 138: 3410 -3416, 1997) C LASSICALLY, the physiological roles of aldosterone in circulatory homeostasis and salt/water balance were thought to be mediated via epithelial mineralocorticoid receptors (MR) (1). More recently, there is increasing evidence for nongenomic actions of aldosterone (2, 3), and for major cardiovascular effects of aldosterone via classical MR in nonepithelial tissues such as brain and heart. It is now clear, for example, that occupancy of circumventricular MR by aldosterone is necessary for the elevated blood pressure in mineralocorticoid/salt models of experimental hypertension, in that animals given peripheral aldosterone and intracerebroventricular MR antagonists show the peripheral signs of mineralocorticoid excess but no elevation of blood pressure (4, 5). In the heart, aldosterone/excess salt administration has been shown to produce both cardiac hypertrophy and interstitial and perivascular cardiac fibrosis, independent of blood pressure (5, 6), and (at least in the case of collagen deposition) very probably reflecting a direct effect of aldosterone on the heart mediated by cardiac MR (7).
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We have recently shown that MR occupancy by aldosterone (but not corticosterone) increases [ 3 H]leucine incorporation into protein by isolated neonatal rat cardiomyocytes, and that this effect is potentiated by elevated extracellular glucose (8) . In contrast with MR occupancy by aldosterone, glucocorticoid receptor (GR) activation is catabolic, lowering [ 3 H]leucine incorporation, an effect that is not altered by high glucose. The glucose-induced potentiation of aldosterone action is totally blocked by the selective protein kinase C (PKC) inhibitor GF 109203X, which strongly suggests a link between PKC activity and the action of aldosterone, but not glucocorticoids, in cardiomyocytes.
In terms of a more global relationship between these signaling pathways, other recent studies have also shown the involvement of PKC as a possible second messenger in the nonclassical actions of aldosterone. Aldosterone has been reported to stimulate PKC activity in rat distal colon (9) , and to translocate PKC from the soluble to the particulate fraction in rat vascular smooth muscle cells (10) , in each case with a time course of action inconsistent with an effect via classic genomic pathways. Modulation of PKC by aldosterone may thus represent an additional important mechanisms underlying selective aldosterone action. Activation of PKC is generally associated with translocation of the enzyme from the soluble to the particulate fraction, which is thus often used as an index of activation; in this context, translocation of PKC in response to various hormones and peptides has been documented in neonatal rat cardiomyocytes (11, 12) . There is also, however, evidence that translocation of PKC does not always correlate with enzyme activation as measured by substrate phosphorylation (13); for example, PKC isoform does not translocate even when stimulated by phorbol esters (14) . This suggests that measurement of net PKC substrate phosphorylation may constitute a more accurate index of PKC activation than translocation, and we have therefore chosen to determine phosphorylation in vitro to evaluate PKC activity in the present study. We have thus examined the effect of aldosterone and a various other steroids on PKC activity in neonatal rat cardiomyocytes, to further explore the actions of aldosterone in this nonepithelial tissue.
Biomedicals (Sydney, Australia). RU 28318, a type I (mineralocorticoid) receptor antagonist, was provided by Roussel-UCLAF (Paris, France). All other chemicals were of the highest purity commercially available. Steroid hormones were dissolved in ethanol, and the final concentration of ethanol in all assays was less than 0.01%, at which concentration ethanol was without effect on PKC activity in our assay system.
Cell culture
Enriched cultures of neonatal (day 1-3) cardiomyocytes were prepared from hearts of Sprague-Dawley rats by a previously described enzymatic method (8) . After treatment with collagenase type II (Sigma), and subsequent digestion with trypsin and deoxyribonuclease, cells were resuspended in complete medium [50% (vol/vol) DMEM, 50% (vol/vol) Ham's F-12 medium, 1% nonessential amino acids, 2 mm l-glutamine, penicillin (100 U/ml), streptomycin (100 g/ml)] containing 10% FCS, and incubated for 40 min at 37 C, allowing selective attachment of nonmyocytes. Cardiomyocyte-enriched suspensions were plated in complete medium containing 10% FCS. The culture medium was changed to complete medium with 10% FCS containing 100 m of the DNA synthesis inhibitor bromodeoxyuridine (BdU) on the second day in culture, and kept at 37 C in a humidified atmosphere of 5% CO 2 in air for a further 2 days. Each dish was incubated with complete serum-free medium [50% (vol/vol) DMEM, 50% (vol/vol) Ham's F-12 medium, 1% BSA (BSA)] for 16 h before experiment. Using this method, we routinely obtained myocyte-rich cultures with at least 95% cardiomyocytes, as assessed by microscopic observation of beating cells and immunofluorescence staining with a monoclonal antibody against atrial natriuretic factor.
Most nonmyocyte-enriched cultures consist of cardiac fibroblasts, which were then cultured in DMEM containing 10% FCS, penicillin (100 U/ml), streptomycin (100 g/ml), and the medium changed every 3 or 4 days. Cardiac fibroblasts between the second and fourth passages were used, after having been incubated with serum-free DMEM for 16 h.
Determination of PKC activity
Preparation of cardiomyocyte soluble and particulate fractions was by a previously described method (8) . Cells were washed twice with ice-cold PBS, and scraped into ice-cold buffer I containing 0.25 m sucrose, 10 mm MOPS, 2.5 mm EGTA, 2.0 mm EDTA, 100 m leupeptin, and 200 m phenylmethylsulfonyl fluoride. The cells were sonicated twice for 10 sec on ice, and centrifuged at 100,000 ϫ g for 60 min at 4 C, with the supernatant taken as soluble fraction. The pellet was resuspended in buffer I, solubilized with 0.5% (vol/vol) Tween-20 for 30 min on ice, sonicated, centrifuged at 100,000 ϫ g for 60 min at 4 C, and the supernatant taken as the particulate fraction. Protein levels were determined by the method of Bradford (Pierce Chemical, Rockford, IL) with BSA as standard. PKC assays were performed at 30 C in a final volume of 40 l of incubation mixture containing either soluble or particulate fraction with 30 mm Tris-HCl, pH 7.4, 10 mm MgCl 2 , 200 m CaCl 2 , 200 m [␥-32 P]ATP, 100 g/ml or 50 g/ml myristoylated alanine-rich C kinase substrate (MARCKS), 10 g/ml phosphatidylserine, and 10 g/ml diolein, as previously described (15) . Parallel incubations performed in the absence of phosphatidylserine and diolein were also included. Reactions were allowed to proceed for 15 min, except in time-course studies, and incubations stopped by adding 8 l of 375 mm orthophosphoric acid at 4 C. Subsequently, 30 l aliquots of the reaction mixture were spotted onto 2 ϫ 2 cm squares drawn on a Whatman P-81 phosphocellulose paper and then washed once for 10 min in 75 mm orthophosphoric acid, twice for 5 min in distilled water and then for 5 min in 95% ethanol. After washing, the paper was dried, cut into individual squares, placed in individual scintillation vials, and radioactivity counted in a scintillation spectrometer. PKC activity was expressed as picomoles of Pi/min/mg of protein.
Purification of PKC
PKC was purified to homogeneity from adult Sprague-Dawley rat brains by a previously described method (16) , made 10% with glycerol and 0.05% with Triton X-100, and stored at Ϫ80 C. This PKC preparation has been shown to be very active in phosphorylating MARCKS in the presence of Ca 2ϩ and phosphatidylserine (Ca 2ϩ /phosphatidylserinedependent), and to be activated by PMA in a concentration-dependent manner (16). After washing with 50 mm Tris-HCl three times under vacuum, the membrane was removed and air dried. The dried membrane was exposed to a BAS-TR2040S imaging screen, and then analyzed by phosphoimage analysis (BAS, Fuji, Tokyo, Japan), and/or cut into individual pieces and the radioactivity counted. Overlay-binding assay was performed by a previously described method (17); different concentrations of purified PKC were blotted onto a nitrocellulose membrane in a slot-blot transfer apparatus, washed twice for 5 min in 5 mm imidazole (pH 7.4), and then incubated in a solution containing 5 mm imidazole, 60 mm KCl, 5 mm MgSO 4 
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Statistical analysis
Data are expressed as mean Ϯ sem, and statistical significance assessed by one-way ANOVA followed by Fisher's PLSD test for post hoc comparisons, with P values of Ͻ 0.05 taken as significant.
Results
Effect of aldosterone on basal PKC activity in cardiomyocytes
In the presence of phosphatidylserine, diolein and calcium, basal levels of PKC activity have been determined in both soluble and particulate fractions isolated from neonatal rat cardiomyocytes. In these cultured cells, 79% of basal PKC activity is associated with the soluble fraction, and the remainder localized to the particulate fraction. Aldosterone (1 nm) lowered basal PKC activity in both soluble and particulate fractions (Fig. 1A) . Given the much higher basal levels of PKC activity in the soluble fraction, and the greater relative repression by aldosterone (Fig. 1) , we have chosen this fraction for further studies. Figure 1B shows the time course of the effect of aldosterone (solid circles) and PMA (open squares) on PKC activity. Soluble fractions were incubated for the time indicated with 1 nm aldosterone or 100 nm PMA, and PKC activity measured. PMA produced a significant increase in PKC activation after 2 min incubation (125 Ϯ 12% of control; P Ͻ 0.05), and reached plateau levels at 15-20 min. In contrast, aldosterone very rapidly lowered basal PKC activity in the same cultured cells within 1 min (75 Ϯ 2% of control; P Ͻ 0.05), reaching 52 Ϯ 12% of control at 15 min. Figure 2A shows the effect of different concentrations of aldosterone on basal PKC activity. Soluble fractions were incubated with the indicated concentration of aldosterone for 15 min and PKC activity measured. Lowering of PKC activity became apparent at 1 nm aldosterone, reaching a plateau at 10 nm. A similar dose-response study was performed to explore the effects of corticosterone on PKC activity in neonatal cardiomyocytes. As shown in Fig. 2B , corticosterone was without effect on PKC activity at physiological plasma free concentrations, but lowered basal PKC activity at higher concentrations (100 nm-1 m). These results suggest that aldosterone can selectively repress basal PKC activity in neonatal rat cardiomyocytes, in that corticosterone is almost two order of magnitude less potent in this regard.
Effects of other steroid hormones on basal PKC activity in cardiomyocytes
Next, the effect of various steroid hormones on basal PKC activity in cardiomyocytes was examined. Soluble fractions isolated from cardiomyocytes were incubated with 10 nm of each steroid hormones for 15 min, and PKC activity measured. As shown in Fig. 3 , the potent mineralocorticoid 9␣-fluorocortisol represses basal PKC activity to a similar extent as aldosterone. The same concentration (10 nm) of deoxycorticosterone has considerably lower potency in terms of repressive effects on basal PKC activity; estradiol has a minimal but significant effect, and progesterone was without effect. The dose-response curve for 9␣-fluorocortisol was similar to that of aldosterone, with a substantial effect on basal PKC activity at 1 nm; in contrast, a significant effect for deoxycorticosterone was first seen at 10 nm (data not shown).
Effects of aldosterone on PMA-stimulated PKC activity in cardiomyocytes
To determine whether aldosterone modulates not only basal but also PMA-stimulated PKC activity in cardiomyocytes, cells were incubated with PMA and the effects of aldosterone determined. As previously shown in Fig. 1, 100 nm PMA produced a significant increase in PKC activation after 15 min incubation (P Ͻ 0.01 vs. basal value). Coincubation with aldosterone at as low as 1 nm lowered PMAstimulated PKC activity, an effect of aldosterone that is dose dependent (Fig. 4) . The dose-response curve for aldosterone on PMA-stimulated PKC activity is clearly parallel to that for basal PKC activity, with plateau levels of repression at aldosterone concentrations of Ն (Fig. 2) ; however, even at high concentrations of aldosterone, PKC activity is not repressed to the level seen with 10 nm aldosterone alone (compare PMA ϩ 10 nm Aldo with Aldo 10 nm alone). On the other hand, the percent fall in PMA-stimulated PKC levels with aldosterone (26%) is indistinguishable from that seen with 10 nm aldosterone in the absence of PMA (29%), suggesting equivalent sensitivity of basal and PMA-stimulated PKC activity.
Effects of calcium on aldosterone inhibition of PKC activity in cardiomyocytes
There has been considerable interest in identifying the PKC isozymes expressed by cardiomyocytes, although the results to date are inconclusive. This may reflect differences in experimental conditions and techniques, and to differential sensitivity of the anti-PKC antibodies used in each study. Recent studies, however, have generally shown that in neonatal rat cardiomyocytes conventional Ca 2ϩ -sensitive PKC isozymes, novel Ca 2ϩ -insensitive PKC isozymes, and an atypical PKC isozyme are coexpressed, whereas in adult cardiomyocytes only the novel Ca 2ϩ -insensitive PKC isozymes are detectable (11, 18, 19) . To examine the effect of calcium on aldosterone inhibition of PKC activity, soluble fractions were incubated with aldosterone at various concentrations of calcium. As shown in Fig. 5A , addition of Ca 2ϩ (200 m) more than doubles the level of PKC activation compared with phosphatidylserine and diolein alone. These results are consistent with earlier studies (11, 18) showing that in neonatal rat cardiomyocytes Ca 2ϩ -sensitive PKC isozymes are expressed. In the present studies, Ca 2ϩ -dependent-PKC activation was observed over the 25-200 m Ca 2ϩ concentration range (Fig. 5B, open circles) . Aldosterone (10 nm; Fig. 5B, closed circles) repressed Ca 2ϩ -dependent-PKC activation, with a similar degree of repression at each Ca 2ϩ -concentration (61 Ϯ 2% at 200 m Ca 2ϩ , 66 Ϯ 2% at 100 m, 70 Ϯ 1% at 50 m, 66 Ϯ 2% at 25 m). These data suggest that inhibitory effect of aldosterone on PKC activity is essentially independent of Ca 2ϩ concentration, and that in contrast with the case for PMA, both Ca 2ϩ independent and Ca 2ϩ dependent isozymes are similarly aldosterone sensitive.
Aldosterone does not directly bind to PKC
To evaluate a possible direct interaction of aldosterone and PKC, two different binding assays were performed. First, purified PKC (4.4 g) was incubated with 0.5-10 nm [
3 H]aldosterone alone or with excess nonradioactive aldosterone, and then filtered onto a nitrocellulose membrane in a slotblot transfer apparatus. After vigorous washing with 50 mm Tris-HCl, the membrane was exposed to a BAS-TR2040S imaging screen, and then either analyzed by phosphoimaging, or cut and the radioactivity counted. As shown in Fig.  6A, no specific binding 
Effects of spironolactone on basal and aldosterone-inhibited PKC activity in cardiomyocytes
To examine the possibility that aldosterone inhibition of basal PKC activity is via classical MR, the effect of the MR antagonist spironolactone was determined. Soluble fractions were incubated with 10 nm aldosterone or various concentrations of spironolactone alone, or 10 nm aldosterone plus 1 m spironolactone, for 15 min and PKC activity measured. As shown in Fig. 7 , spironolactone at low concentrations was without effect on basal PKC activity; at 100 nm, 1 m, spironolactone repressed basal PKC activity but to an apparent plateau level significantly higher than that seen with aldosterone. Of particular interest, 1 m spironolactone did not ameliorate the effect of 10 nm aldosterone, which might be expected if the two steroids were competing for a common binding site on MR. We have also used the more selective MR antagonist, RU 28318, and found similar results to those shown for spironolactone.
Aldosterone affects neither basal nor PMA-stimulated PKC activity in cardiac fibroblasts
Even in cultures enriched for cardiomyocytes, there is a very minor population of residual nonmyocytes, most of which are cardiac fibroblasts. To exclude the possibility of a major confounding effect of fibroblasts on our cardiomyocyte cultures, we have determined whether aldosterone represses basal PKC and/or PMA-stimulated PKC activity in cultures of cardiac fibroblasts. Soluble fractions isolated from cultures enriched for cardiac fibroblasts were incubated with aldosterone, PMA or PMA plus aldosterone for 15 min, and PKC activity measured. As shown in Fig. 8 , basal PKC activity was much less in cardiac fibroblasts (116 Ϯ 10 pmol/ min⅐mg) than in cardiomyocytes. Aldosterone (1-100 nm) was without effect on basal PKC activity in cardiac fibroblasts, as were the same concentrations of deoxycorticosterone and 9␣-fluorocortisol. PMA (100 nm) produced a near doubling of PKC activation (224 Ϯ 8 pmol/min/mg, P Ͻ 0.01 vs. basal), and aldosterone (10 nm) had no effect on PMAstimulated PKC activity. These results argue that inhibitory effect of aldosterone on PKC activity is cardiomyocyte specific, given that aldosterone clearly does not affect PKC activity in cardiac fibroblasts.
Discussion
In the present study, we have shown that aldosterone rapidly represses basal PKC activation in neonatal rat cardiomyocytes, and that this effect is unlikely to be caused by a direct interaction between aldosterone and PKC. Both   FIG. 6 . A, Direct binding assay using 0.5-10 nM [
3 H]aldosterone and purified PKC (4.4 g). After incubation, the assay mixture was filtered onto a nitrocellulose membrane and the membrane analyzed by imaging system (BAS) or cut into individual pieces and radioactivity counted. Two independent experiments were performed, and no specific binding was seen. B, Overlay binding assay; purified PKC (440 ng/l) was spotted onto a nitrocellulose membrane, and incubated with -sensitive and Ca 2ϩ -insensitive PKC isozymes appear inhibited by aldosterone, and PMA-stimulated PKC activation appears similarly sensitive to aldosterone as does basal. The hierarchy of potency in terms of steroid action in difficult but not impossible to reconcile with classical MR being involved as an intermediate. Finally, in cardiac fibroblasts aldosterone affects neither basal nor PMA-stimulated PKC activity, which strongly suggests that the aldosterone-PKC interaction is tissue/cell specific and that tissue/cell specific factor(s) may mediate the action of aldosterone on PKC activity.
PKC comprises a family of serine-threonine protein kinases, which have a number of key cellular functions (20, 21) . In the heart, PKC has been implicated as a candidate mediator of cardiomyocyte hypertrophy, and of contractility and ion exchange activity (22) . Whereas PKC activity is regulated physiologically by membrane receptor-mediated production of diacylglycerol, and experimentally by phorbol esters such as PMA, there are an increasing number of reports of steroids as effectors in the PKC system. At the level of gene expression, thyroid hormone has been shown to repress PKC␣ expression in neonatal heart, and PKC⑀ in both neonatal and adult heart (23) . At the other end of the scale, purified enzyme preparations of PKC␣, PKC␥ and PKC⑀ have been reported to be directly activated by 1,25 dihydroxy vitamin D 3 , in a system containing only purified enzyme, substrate, cofactors and lipid vesicles (24) . The concentrations of vitamin D 3 required in the above study were 10 -100 nm, approximately three orders of magnitude higher than those required for binding to classical vitamin D 3 receptors and producing genomic effects.
Effects of aldosterone on the PKC system have also been reported. In previous studies from this laboratory (3), the rapid nongenomic effects of aldosterone on intracellular Ca 2ϩ in vascular smooth muscle cells were modulated by PMA and staurosporine, suggesting participation of PKC in the signaling process. In the rat distal colon (9), aldosterone has been reported to increase PKC activity greater than or equal to 10-fold over basal in cytosolic fractions within 15 min; 9␣-fluorocortisol produced a similar level of increase, whereas deoxycorticosterone (5-fold), estradiol (2-to 3-fold), and cortisol (1.5-to 2-fold) showed lower levels of activation over basal. Interpretation of these data are difficult, in that for all steroids tested indistinguishable levels of stimulation were found over the concentration range 10 pm to 100 nm. The potential physiologic role for such an effect independent of dose over the range of normally circulating concentrations remains to be established.
Whereas the steroid concentration required for the 1,25 dihydroxy vitamin D 3 effect (24) appear orders of magnitude higher than circulating levels, and those for modulation of PKC activity in colonic cells (8) orders of magnitude lower, the dose-response data found in the present study are compatible with a graded cellular response to changes in plasma concentration over the normal physiologic range. For aldosterone, the EC 50 for effects on cardiomyocyte PKC activity lies between 0.1 and 1 nm, in line with previous studies by Wehling and his colleagues on rapid, nongenomic effects of aldosterone in a variety of tissues (25) . The hierarchy of steroid potency is similar but not identical to that found in such studies, with 9␣-fluorocortisol essentially equivalent to aldosterone, and deoxycorticosterone active but requiring rather higher concentrations. Where the present study differs in this regard is that previously (25) the physiologic glucocorticoids were found to be devoid of agonist activity, even at concentrations 1000x those of aldosterone, and spironolactone similarly without aldosterone antagonist activity. In the present study, in contrast, corticosterone mimics aldosterone, although requiring two orders of magnitude higher concentrations to do so, and, at similarly high concentrations, spironolactone appears to act as a partial agonist for the aldosterone induced response, with no apparent antagonist activity, a finding difficult to reconcile with current models of partial agonist/antagonist action.
The question to be addressed, in the context of these steroid specificity studies, is that of how the nanomolar concentrations of aldosterone are recognized, and the mechanism whereby that recognition is transduced into a signal affecting PKC activity. The nanomolar concentrations at which the effects of aldosterone are seen require a high affinity recognition system, which presumably involves binding to protein. We have shown that purified PKC preparations do not bind aldosterone with high affinity, a finding extrapolated to the whole cell milieu with some caution; at first sight, the present specificity data might be interpreted as excluding a rapid, nongenomic action for classical MR, leaving open the possibility of aldosterone acting by binding to some other membrane or intracellular protein/channel/ effector. On the other hand, it may be premature to exclude protein-protein interactions involving classical MR as mediating the rapid effects of aldosterone and the other steroids examined on cardiomyocyte PKC activity. Such protein-protein interactions have been demonstrated for GR with both AP-1 and NFB protein complexes (26 -28) . Secondly, whereas classical MR have been widely reported to have very similar affinity for aldosterone and the physiologic glucocorticoids (29, 30) , in transfection system aldosterone has been reported to be equivalent to (31) , ten times more potent than (32) or even 100 times more potent than physiologic glucocorticoids (33) , with the mechanism underlying the differences in observed potency yet to be established. Finally, in epithelial MR corticosterone and cortisol mimic the action of aldosterone, whereas in nonepithelial MR the physiologic glucocorticoids act, like spironolactone, as aldosterone antagonists (34); again, the basis for this difference is unclear. In the final analysis, a possible role for classical MR in the rapid PKC response will be excluded or established by studies in the mineralocorticoid receptor knockout mouse, anticipated to be available in the relatively near future.
In previous studies we have shown that high glucose elevates PKC activity in neonatal cardiomyocytes, and that this elevation of PKC has profound effects on MR-mediated actions of aldosterone in these cells (8) . Specifically, the threshold for aldosterone action (on [ 3 H]leucine incorporation into protein) is lowered by an order of magnitude, thus very much enhancing the sensitivity of the cell to ambient concentrations of steroid. The effect on MR is aldosterone-specific, in that it is not seen when MR are occupied by corticosterone, and abrogated by the selective PKC inhibitor GF109203X. The present studies suggest that an intracellular negative feedback control system may operate for PKC and aldosterone in these nonepithelial cells, with aldosterone rapidly but modestly lowering PKC activity, and PKC activation increasing by an order of magnitude the potency of aldosterone at the genomic level, on at least one index of gene expression. The mechanisms involved in this cross-talk between the two signaling systems, and the pathophysiologic implications thereof, await further investigation.
